FDMT. – 4D Molecular Therapeutics Inc
FDMT — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
22.86
Margin Of Safety %
Put/Call OI Ratio
0.52
EPS Next Q Diff
-1.42
EPS Last/This Y
-1.39
EPS This/Next Y
0.01
Price
10.26
Target Price
29.38
Analyst Recom
1.5
Performance Q
40.27
Upside
-418.7%
Beta
3.03
Ticker: FDMT
16 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | FDMT | 8.74 | 0.23 | 0.00 | 3240 |
| 2026-03-10 | FDMT | 8.87 | 0.23 | 0.08 | 3243 |
| 2026-03-11 | FDMT | 8.54 | 0.23 | 0.15 | 3255 |
| 2026-03-12 | FDMT | 8.47 | 0.23 | 2.86 | 3245 |
| 2026-03-13 | FDMT | 8.45 | 0.23 | 2.86 | 3245 |
| 2026-03-17 | FDMT | 8.6 | 0.24 | 87.31 | 3303 |
| 2026-03-18 | FDMT | 8.57 | 0.66 | 999.99 | 4433 |
| 2026-03-20 | FDMT | 8.63 | 0.77 | 1.67 | 4526 |
| 2026-03-25 | FDMT | 9.89 | 0.58 | 0.57 | 4421 |
| 2026-03-26 | FDMT | 10.19 | 0.59 | 0.24 | 4431 |
| 2026-03-27 | FDMT | 9.33 | 0.60 | 0.02 | 4473 |
| 2026-03-30 | FDMT | 8.57 | 0.58 | 7.13 | 4568 |
| 2026-03-31 | FDMT | 9.32 | 0.58 | 0.01 | 4572 |
| 2026-04-01 | FDMT | 9.87 | 0.56 | 0.01 | 4669 |
| 2026-04-06 | FDMT | 9.95 | 0.56 | 0.00 | 4659 |
| 2026-04-07 | FDMT | 10.25 | 0.52 | 0.00 | 4912 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
16 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | FDMT | 8.72 | 41.3 | - | -3.26 |
| 2026-03-10 | FDMT | 8.86 | 41.3 | - | -3.26 |
| 2026-03-11 | FDMT | 8.53 | 41.3 | - | -3.26 |
| 2026-03-12 | FDMT | 8.46 | 41.3 | - | -3.26 |
| 2026-03-13 | FDMT | 8.35 | 41.3 | - | -3.26 |
| 2026-03-17 | FDMT | 8.61 | 41.3 | - | -3.26 |
| 2026-03-18 | FDMT | 8.56 | 41.3 | - | -3.26 |
| 2026-03-19 | FDMT | 8.99 | 41.3 | - | -3.26 |
| 2026-03-20 | FDMT | 8.61 | 41.3 | - | -3.26 |
| 2026-03-23 | FDMT | 9.23 | 41.3 | - | -3.26 |
| 2026-03-24 | FDMT | 9.19 | 41.3 | - | -3.26 |
| 2026-03-25 | FDMT | 9.89 | 41.3 | - | -3.26 |
| 2026-03-26 | FDMT | 10.19 | 41.3 | - | -3.26 |
| 2026-03-27 | FDMT | 9.32 | 41.3 | - | -3.26 |
| 2026-03-30 | FDMT | 8.57 | -17.3 | - | -3.75 |
| 2026-03-31 | FDMT | 9.31 | -17.3 | - | -3.75 |
| 2026-04-01 | FDMT | 9.86 | -17.3 | - | -3.75 |
| 2026-04-02 | FDMT | 9.47 | -17.3 | - | -3.75 |
| 2026-04-06 | FDMT | 9.96 | -16.7 | - | -3.81 |
| 2026-04-07 | FDMT | 10.26 | -16.7 | - | -3.81 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | FDMT | -0.23 | 30.14 | 21.38 |
| 2026-03-10 | FDMT | -0.23 | 30.14 | 21.38 |
| 2026-03-11 | FDMT | -0.23 | 30.14 | 22.29 |
| 2026-03-12 | FDMT | -0.23 | 30.14 | 22.29 |
| 2026-03-13 | FDMT | -0.23 | 30.14 | 22.29 |
| 2026-03-18 | FDMT | -0.23 | 30.01 | 22.29 |
| 2026-03-19 | FDMT | -0.23 | 30.01 | 22.29 |
| 2026-03-20 | FDMT | -0.23 | 30.01 | 22.29 |
| 2026-03-23 | FDMT | -0.23 | 34.97 | 22.27 |
| 2026-03-24 | FDMT | -0.23 | 34.97 | 22.27 |
| 2026-03-25 | FDMT | -0.24 | 34.97 | 22.86 |
| 2026-03-26 | FDMT | -0.24 | 34.97 | 22.86 |
| 2026-03-27 | FDMT | -0.19 | 34.97 | 22.86 |
| 2026-03-30 | FDMT | -0.19 | 30.04 | 22.86 |
| 2026-03-31 | FDMT | -0.19 | 30.04 | 22.86 |
| 2026-04-01 | FDMT | -0.19 | 30.04 | 22.86 |
| 2026-04-02 | FDMT | -0.19 | 30.04 | 22.86 |
| 2026-04-06 | FDMT | -0.19 | 30.04 | 22.86 |
| 2026-04-07 | FDMT | -0.19 | 30.04 | 22.86 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
0.43
Avg. EPS Est. Current Quarter
-1.01
Avg. EPS Est. Next Quarter
-0.99
Insider Transactions
-0.19
Institutional Transactions
30.04
Beta
3.03
Average Sales Estimate Current Quarter
3
Average Sales Estimate Next Quarter
2
Fair Value
Quality Score
23
Growth Score
53
Sentiment Score
63
Actual DrawDown %
76.2
Max Drawdown 5-Year %
-94.1
Target Price
29.38
P/E
Forward P/E
PEG
P/S
6.14
P/B
1.17
P/Free Cash Flow
EPS
-2.51
Average EPS Est. Cur. Y
-3.81
EPS Next Y. (Est.)
-3.8
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-164.43
Relative Volume
1.35
Return on Equity vs Sector %
-55.2
Return on Equity vs Industry %
-38.6
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.33
EBIT Estimation
◆
FDMT
Healthcare
$10.24
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
20/20
Pullback
6/25
Volume
3/15
Valuation
9/20
TP/AR
2/10
Options
7/10
RSI
59.4
Range 1M
82.3%
Sup Dist
5.7%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
12/25
Growth
14/30
Estimates
1/20
Inst/Vol
11/15
Options
5/10
EPS Yr
-58.1%
EPS NY
-0.8%
52W%
79%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+186.9% upside
Quality
6/30
Valuation
16/30
Growth
8/25
Stability
9/10
LT Trend
4/5
Upside
+186.9%
Quality
23
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 196
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
FDMT
Latest News
—
Caricamento notizie per FDMT…
stock quote shares FDMT. – 4D Molecular Therapeutics Inc Stock Price stock today
news today FDMT. – 4D Molecular Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch FDMT. – 4D Molecular Therapeutics Inc yahoo finance google finance
stock history FDMT. – 4D Molecular Therapeutics Inc invest stock market
stock prices FDMT premarket after hours
ticker FDMT fair value insiders trading